Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8168663	FOLDRX PHARMS	Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof	Dec, 2023 (4 months ago)
US7214695	FOLDRX PHARMS	Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding	Dec, 2024 (7 months from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653119	FOLDRX PHARMS	Methods for treating transthyretin amyloid diseases	Dec, 2023 (4 months ago)
US7214696	FOLDRX PHARMS	Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding	Dec, 2024 (7 months from now)

Vyndaqel is owned by Foldrx Pharms.

Vyndaqel contains Tafamidis Meglumine.

Vyndaqel has a total of 4 drug patents out of which 2 drug patents have expired.

Expired drug patents of Vyndaqel are:

Vyndaqel was authorised for market use on 03 May, 2019.

Vyndaqel is available in capsule;oral dosage forms.

Vyndaqel can be used as treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm).

Drug patent challenges can be filed against Vyndaqel from 04 May, 2023.

The generics of Vyndaqel are possible to be released after 03 May, 2026.

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 03, 2024
Orphan Drug Exclusivity(ODE-237)	May 03, 2026

NCE-1 date: 04 May, 2023

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

Vyndaqel patents expiration